-
12:29:32 PM

CSTL Stock News

03/18/23 7:00 AM
Nasdaq : CSTL
Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today shared new performance data from a novel, multi-center, independent cohort demonstrating how the independent risk-stratification of DecisionDx ®- SCC can significantly improve metastatic risk predictions by complementing current staging...
RHEA-AI
very positive
03/14/23 7:00 AM
Nasdaq : CSTL
conferences
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences& MedTech Investor Forum on Wednesday,...
RHEA-AI
neutral
03/10/23 7:00 AM
Nasdaq : CSTL
Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced that new data supporting its portfolio of skin cancer gene expression profile tests will be showcased in one late-breaking oral presentation and three ePosters at the 2023 American Academy of Dermatology Annual Meeting, being held March...
RHEA-AI
neutral
03/08/23 7:00 AM
Nasdaq : CSTL
Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced the publication of a consensus panel report from the National Society for Cutaneous Medicine recommending use of gene expression profile testing in the clinical assessment and management of cutaneous melanoma. “DecisionDx-Melanoma...
RHEA-AI
positive
02/24/23 7:00 AM
Nasdaq : CSTL
Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced that its chief financial officer, Frank Stokes, was named to Finance& Investing’ s Top 25 CFOs of Houston list for 2023. “I am proud of Frank’ s accomplishments at Castle,” said Derek Maetzold, president and chief executive officer of Castle...
RHEA-AI
neutral
02/22/23 7:00 AM
Nasdaq : CSTL
Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx ®- Melanoma and the Company’ s pipeline test for inflammatory skin diseases was presented at the recent 2023 Winter Clinical- Miami™ conference. The poster presentation for DecisionDx ®- Melanoma strengthens the...
RHEA-AI
neutral
02/09/23 5:00 PM
Nasdaq : CSTL
Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced the publication of data from a prospective, multicenter study, called DECIDE. 1,2 In the study, DecisionDx ®- Melanoma test results influenced 85% of clinicians’ decisions regarding the sentinel lymph node biopsy surgical procedure.
RHEA-AI
neutral
02/07/23 5:00 PM
Nasdaq : CSTL
earnings
Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023. To access the live conference call via phone, please dial 1 844 200 6205 from the United States, or +1...
RHEA-AI
neutral
02/01/23 5:00 PM
Nasdaq : CSTL
Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced that it has received a 2023 Top Workplaces USA award from Energage. “We are incredibly honored to have once again earned a Top Workplaces USA award,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.“ At Castle, we...
RHEA-AI
very positive